leadership
Co-Founder: Adam Kaplin, MD, PhD
Chairman and Advisor: David Vorhoff
Co-Founder: Jonathan Helfgott, MS
Dr. Adam Kaplin, a neuropsychiatrist trained at Yale and Johns Hopkins, combines extensive startup experience with deep expertise in CNS drug development. He is dedicated to advancing groundbreaking treatments for neurological and psychiatric disorders, bringing visionary leadership to Minerve Pharmaceuticals.
Co-Founder: Jonathan Helfgott, MS
Chairman and Advisor: David Vorhoff
Co-Founder: Jonathan Helfgott, MS
Jonathan Helfgott is a regulatory expert with extensive experience and strong ties to the FDA. He specializes in guiding CNS drug development with strategic regulatory insight and ensuring compliance, accelerating the pathway from innovation to patient care.
Chairman and Advisor: David Vorhoff
Chairman and Advisor: David Vorhoff
Scientific Advisory Board: Zaven Khachaturian, PhD
David Vorhoff, Chairman of Foro, brings a wealth of expertise in finance and business development. His strategic vision and leadership support Minerve’s growth and long-term success.
Scientific Advisory Board: Zaven Khachaturian, PhD
Scientific Advisory Board: Zaven Khachaturian, PhD
Scientific Advisory Board: Zaven Khachaturian, PhD
Dr. Zaven Khachaturian, a pioneer in Alzheimer’s research, provides invaluable guidance on scientific and therapeutic strategy. His groundbreaking work has shaped the understanding and treatment of neurodegenerative diseases.
Scientific Advisory Board: Ara Khachaturian, PhD
Scientific Advisory Board: Zaven Khachaturian, PhD
Scientific Advisory Board: Ara Khachaturian, PhD
Dr. Ara Khachaturian, Ph.D. is a leader in public health policy, specializing in epidemiology, biomedical research, and complex modeling. He is Executive Vice-President of Prevent Alzheimer’s 2020, Inc. and founding Executive Editor of the Alzheimer’s & Dementia journal series. Dr. Khachaturian is also a Senior Research Fellow at the National Supercomputing Institute at UNLV.
Scientific Advisory Board: Michael Levy, MD, PhD
Scientific Advisory Board: Zaven Khachaturian, PhD
Scientific Advisory Board: Ara Khachaturian, PhD
Dr. Michael Levy, Director of the Neuroimmunology Clinic at Harvard’s Massachusetts General Hospital, provides critical expertise in neuroimmunology, supporting Minerve’s mission to address neurodegenerative diseases with innovative therapeutic strategies.
Intellectual Property Development: Richard Warburg
Intellectual Property Development: Richard Warburg
Intellectual Property Development: Richard Warburg
Richard Warburg and his team at Godney Holdings deliver comprehensive intellectual property strategy and management, ensuring Minerve Pharmaceuticals’ innovations are protected and positioned for success in a competitive market.